That’s it for Avandia. The FDA has put the TIDE trial "on full clinical hold and the regulatory deadlines for its conduct are rescinded." The plan is to reassess the data from the RECORD trial to see if reliable "ischemic risk can be obtained from [] re-adjudication…" In Europe physicians have been directed to stop prescribing the drug. Meanwhile, in the U.S., patients will still be able to get the drug if they are already on it or have tried other drugs like pioglitazone without success.